Stroke survivors get new hope: major trial tests colchicine and ticagrelor to prevent repeat attacks.

NCT ID NCT05476991

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial is testing whether two drugs—colchicine (used for gout) and ticagrelor (a blood thinner)—can prevent future strokes, heart attacks, and other vascular events in people who have already had a stroke. About 2,800 high-risk participants will be enrolled. The goal is to see if adding these drugs to standard care reduces inflammation and clotting, lowering the chance of another event.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Colchicine and ticagrelor
What this could lead to: If successful, this could provide a new way to reduce the risk of another stroke or heart attack in people who have already had a stroke.
What could go wrong: This is a large phase 3 trial, but it is still testing whether these drugs work better than current treatments. There may be side effects like bleeding or stomach issues, and the results may not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome atherosclerosis cerebral infarction heart disorder intermediate coronary syndrome ischemic stroke myocardial infarction stroke disorder transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROSIS CARDIAC DISEASE CEREBRAL INFARCTION CORONARY SYNDROME MYOCARDIAL INFARCTION STROKE STROKE, ISCHEMIC TIA

Contacts and locations

Locations

URC Lariboisière-Fernand Widal-Saint Louis
RECRUITING

Paris, Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.